Concepedia

Avi Bar-Joseph

AB

Statistics

Publications

7

Citations

236

H-Index

7

Active since

1994

Affiliations

Weizmann Institute of Science(Current)

Hebrew University of Jerusalem

Avi Bar-Joseph is an author at Weizmann Institute of Science specializing in neuropharmacology, medicine, and neuroprotection.

Top concepts

Publications per year

1994–2003

7

Publications

7

Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid.

Ruth Gallily, Aviva Yamin, Yaakov Waksmann et al. · PubMed · 1997 · 67 citations

, , +21

Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils

Avi Bar-Joseph, Yafit Berkovitch, Jana Adamchik et al. · Molecular and Chemical Neuropathology · 1994 · 57 citations

, , +10

A Novel Synthetic Cannabinoid Derivative Inhibits Inflammatory Liver Damage via Negative Cytokine Regulation

Iris Lavon, Tatiana Sheinin, Sigal Meilin et al. · Molecular Pharmacology · 2003 · 30 citations

Protection Against Septic Shock and Suppression of Tumor Necrosis Factor α and Nitric Oxide Production by Dexanabinol (HU-211), a Nonpsychotropic Cannabinoid

Ruth Gallily, Aviva Yamin, Yaakov Waksmann et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 29 citations

HU-211, a nonpsychotropic cannabinoid, improves neurological signs and reduces brain damage after severe forebrain ischemia in rats

Ludmila Belayev, Avi Bar-Joseph, Jana Adamchik et al. · Molecular and Chemical Neuropathology · 1995 · 25 citations

, , +17

1–5 of 7